Recent advances in the research of medicinal cannabis has placed the non-intoxicating
cannabinoid cannabidiol (CBD) at the front of scientific research. The reasons behind this …

The number of lipophilic drug candidates in pharmaceutical discovery pipelines has
increased in recent years. These drugs often possess physicochemical properties that result …

Cannabidiol (CBD), a phytocannabinoid compound of Cannabis sativa, shows limited oral
bioavailability due to its lipophilicity and extensive first-pass metabolism. CBD is also known …

Abstract Cannabidiol (CBD), a non‐psychotropic phytocannabinoid from the Cannabis plant,
is increasingly being pursued as a treatment for differing ailments. The bioavailability and …

The poor physicochemical properties of cannabidiol (CBD) hamper its clinical development.
The aim of this review was to examine the literature to identify novel oral products and …

Herein, medium-chain triglycerides (MCT), glyceryl monolinoleate (GML), and a self-
emulsifying drug delivery system (SEDDS) for cannabidiol (CBD) delivery were compared …

Background: Cannabidiol is being pursued as a therapeutic treatment for multiple
conditions, usually by oral delivery. Animal studies suggest oral bioavailability is low, but …

Background and Objectives A wide variety of products containing cannabidiol (CBD) are
available on the commercial market. One of the most common products, CBD oil, is …

Background There is increasing interest in the use of purified cannabidiol (CBD) as a
treatment for a wide range of conditions due to its reported anti-inflammatory, anxiolytic …

Introduction: Cannabidiol (CBD) is a nonintoxicating phytocannabinoid used in clinical
treatments and sold widely in consumer products. CBD products may be designed for …